Prostate Cancer Stroma Lacks Genomic Aberrations

This study evaluates the nuclear and mitochondrial DNA integrity of prostate carcinoma cells, CAS, matched benign epithelium and benign epithelium–associated stroma by whole-genome copy-number analyses, targeted sequencing of TP53, and FISH. Array comparative genomic hybridization (aCGH) of CAS revealed a copy-neutral diploid genome with only rare and small somatic copy-number aberrations (SCNA). In contrast, several expected recurrent SCNAs were evident in the adjacent prostate carcinoma cells, including gains at 3q, 7p, and 8q, and losses at 8p and 10q. No somatic TP53 mutations were observed in CAS. Mitochondrial DNA (mtDNA) extracted from carcinoma cells and stroma identified 23 somatic mtDNA mutations in neoplastic epithelial cells, but only one mutation in stroma. Finally, genomic analyses identified no SCNAs, LOH, or copy-neutral LOH in cultured cancer-associated fibroblasts, which are known to promote prostate cancer progression in vivo.
Implications: The gene expression changes observed in prostate cancer–adjacent stroma and the attendant contribution of the stroma to the development and progression of prostate cancer are not due to frequent or recurrent genomic alterations in the TME. Mol Cancer Res; 14(4); 374–84. ©2016 AACR.

Source: Molecular Cancer Research - April 13, 2016 Category: Cancer & Oncology Authors: Bianchi-Frias, D., Basom, R., Delrow, J. J., Coleman, I. M., Dakhova, O., Qu, X., Fang, M., Franco, O. E., Ericson, N. G., Bielas, J. H., Hayward, S. W., True, L., Morrissey, C., Brown, L., Bhowmick, N. A., Rowley, D., Ittmann, M., Nelson, P. S. Tags: Genomics Source Type: research